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Abstract 
Background: The pathogenesis of irritable bowel syndrome (IBS) is closely related to intestinal dysbacteriosis and 
can be controlled by moxibustion treatment. However, the mechanism underlying the therapeutic value of moxibus-
tion in IBS treatment remains unknown.
Methods: An IBS rat model was established by colorectal distention (CRD) stimulus and mustard oil clyster. Sixty-five 
male rats were randomly divided into six groups: normal, IBS model, moxibustion, electroacupuncture (EA), Bifid-triple 
Viable Capsule (BTVC) and Pinaverium Bromide (PB) groups. The moxibustion group was treated with mild moxibus-
tion at the bilateral Tianshu (ST25) and Shangjuxu (ST37) for 10 min/day for 7 days, the EA group was given EA at ST25 
and ST37 once daily for 7 days, while the BTVC group and PB groups received Bifid-triple Viable Capsule and Pinaver-
ium Bromide solution (at the proportion of 1:0.018) respectively by gavage once daily for 7 days. After the treatment, 
abdominal withdrawal reflex (AWR) scores were determined based on CRD stimulus, gut microbiota profiling was 
conducted by 16S rRNA high-throughput sequencing.
Results: Irritable bowel syndrome model rats had significantly increased AWR scores at all intensities (20, 40, 60 
and 80 mmHg) compared with the normal group. Moxibustion treatment significantly reduced AWR scores com-
pared with the IBS model group at all intensities. Across all groups the most abundant phyla were Bacteroidetes and 
Firmicutes followed by Proteobacteria and Candidatus Saccharibacteria. At genus level IBS model rats had a higher 
abundance of Prevotella, Bacteroides and Clostridium XI and a lower abundance of Lactobacillus and Clostridium 
XIVa compared with normal rats. These changes in microbiota profiles could however be reversed by moxibustion 
treatment. Alpha diversity was decreased in IBS model rats compared with normal rats, yet significantly increased in 
moxibustion- and PB-treated rats compared with IBS rats.
Conclusion: Our findings suggest that moxibustion treats IBS by modulating the gut microbiota.
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Background
Irritable bowel syndrome (IBS) is one of the most com-
mon gastrointestinal disorders, affecting 10–20% of 
the population worldwide [1, 2]. IBS is characterized by 
chronic (continuous or intermittent) abdominal pain, 
bloating, changes in bowel habit and/or stool property. 
IBS has a multifactorial etiology that may include colonic 
dysmotility [3], visceral hypersensitivity [4], brain–gut 
interactions [5], genetic factors [6], post-infectious low-
grade inflammation [7] and altered gut microbiota [8].
Along with the development of microecology theo-
ries, the role of the gut microbiota in IBS has been paid 
increasing attention in recent years. There are trillions of 
bacteria in the human gut that have co-evolved with us 
[9]. The predominant phyla in the human gut are Firmi-
cutes and Bacteroidetes, followed by Proteobacteria, Act-
inobacteria, Fusobacteria and Verrucomicrobia [10]. The 
human gut is home to a rich variety of microbes. Accord-
ingly, the human intestinal track, particularly the colon, 
is equipped with sophisticated regulatory mechanisms 
that facilitate intestinal balance despite complex interac-
tion with the gut microbiota. However, once intestinal 
balance is disturbed chronic diseases including inflam-
matory bowel disease [11], allergic diseases [12], obesity 
[13], colorectal cancer [14] among others [15] may ensue. 
IBS is closely linked to alterations in gut microbiota com-
position [16], which can lead to increased permeabil-
ity of the intestinal mucosal barrier and modulation of 
cytokine secretion, thus playing a significant role in the 
pathophysiology of IBS.
Patients with IBS generally have a reduced quality of 
life [17], underscoring the importance of addressing 
these symptoms. The treatment of IBS ranges from phar-
maceutical to psychological intervention [18]. However, 
long-term use of currently prescribed therapeutics, such 
as 5-hydroxytryptamine receptor (5-HT3) antagonists, 
although partly effective, does have several side effects. 
Psychological treatment does not have any side effects 
but it is difficult to apply effectively long-term. Moxi-
bustion is a traditional Chinese therapy used to improve 
general health and treat chronic conditions by stimulat-
ing specific points with heat generated by burning herbal 
preparations containing dried mugwort leaves [19]. Both 
temperature-related mechanisms and nontemperature-
related mechanisms likely underlie the effects of moxi-
bustion. The latter includes smoke, herbs, and far infrared 
effects [20]. Growing evidence supports moxibustion 
as a safe and effective treatment for IBS [21]. Interest-
ingly, moxibustion has been shown to regulate intestinal 
microbiota [22]. However, few studies have explored the 
effect of moxibustion on the intestinal microbiota. We 
therefore used high-throughput sequencing to determine 
changes in intestinal microbial community structure in 
an IBS rat model with or without moxibustion treatment. 
Our results provide new leads regarding the pathogenesis 
and treatment of IBS.
Materials and methods
The Minimum Standards of Reporting Checklist (Addi-
tional file 1) contains details of the experimental design, 
and statistics, and resources used in this study.
Experimental animals
A total of 65 specific-pathogen free 8-day-old male 
Sprague–Dawley rats were provided by the Department 
of Laboratory Animal Science of Shanghai University of 
Traditional Chinese Medicine. The animals were raised 
under standard conditions at 25 ± 1  °C with a rela-
tive humidity of 50–70% and 12  h light/dark cycle. The 
rats did not separate from their mother until they were 
4  weeks old. All rats were randomly divided into six 
groups: normal (n = 11), model (n = 11), moxibustion 
(n = 11), electroacupuncture (EA, n = 10), Bifid-triple 
Viable Capsule (BTVC, n = 11) and Pinaverium Bromide 
(PB, n = 11). All animal work was performed according 
to the protocols approved by the University Animal Care 
and Use Committee of Shanghai University of Traditional 
Chinese Medicine [IACUC protocol number: SYXK 
(Shanghai) 2009-0082] to reduce pain and to avoid dam-
age. All efforts were made to minimize animal suffering. 
During establishing IBS model rats, operations should be 
slow and soft to avoid causing pain and distress. After the 
procedure, the animals were monitored until fully free to 
move and eat. For animal therapy, be gentle when catch-
ing animals, and take appropriate treatment after the ani-
mals calm down. At the end of the experiment, animals 
received a lethal dose of pentobarbital sodium to mini-
mize animal suffering.
Establishment of the IBS rat model
The IBS rat model was established by colorectal disten-
tion (CRD) through mechanical and chemical stimulus as 
previously described [23]. An inflatable balloon (Shang-
hai Dinghuang Industrial Co., Ltd. China) was slowly 
inserted rectally about 2  cm into the descending colon 
of rats. The balloon was distended with 0.5 ml of air, for 
1 min and then repeated after 30 min. The same disten-
tion was performed for 14 consecutive days between 
the age of 8 and 21 days. After 4 weeks rest, mustard oil 
(0.2 ml, 4%, Shanghai Zhixin Chemical Co., Ltd. China.) 
was injected into the descending colon from the anus 
once a day for 14 days.
Treatment groups
After successful establishment of the model, rats in the 
moxibustion group, EA group, BTVC and PB group 
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received their relevant treatments. For the moxibustion 
group, the ignited moxa stick (0.5 cm in diameter) (Nan-
yang Hanyi Moxa Co., Ltd. China) was placed 2 cm above 
the bilateral Tianshu (ST25) and Shangjuxu (ST37) acu-
points for 10 min/day for 7 days. ST25 is located bilater-
ally 5  mm lateral to the intersection between the upper 
2/3 and the lower 1/3, in the line between the xiphoid 
process and the pubic symphysis upper border and ST37 
is 5  mm lateral to the anterior tubercle of the tibia and 
15 mm below the knee joint [24].
The EA group was given EA at the bilateral Tianshu 
and Shangjuxu acupoints with Han’s Acupoint Nerve 
Stimulator (Beijing Huawei Industrial Development Cor-
poration. China. LH402A) for sparse–dense waves (fre-
quency of sparse wave: 2  Hz, frequency of dense wave: 
10 Hz, intensity: 4 mA) for 20 min, once daily for 7 days. 
The BTVC and PB groups received Bifid-triple Viable 
Capsule (Inner Mongolia Shuangqi Pharmaceutical Co., 
Ltd. China. Lot number: S19980004) and Pinaverium 
Bromide (Abbott Healthcare SAS. France. Lot number: 
H20120127), respectively by gavage, once daily for 7 days. 
The BTVC and PB solutions were prepared as specified 
for a weight ratio of 1:0.018 for an adult (70 kg) and a rat 
(200  g). Prepare the required dose of suspension with 
drinking water. The BTVC solution concentration was 
2 mg/ml with a daily dose of 20 mg/kg. The PB solution 
concentration was 5 mg/ml with a daily dose of 50 mg/
kg. The normal and model groups did not receive any 
treatment. Two rats were died in BTVC group during the 
treatment by gavage.
Abdominal withdrawal reflex (AWR) scores
Abdominal withdrawal reflex scores were calculated to 
assess colon sensitivity to CRD after treatments accord-
ing to Al-Chaer et  al. [23]. Distention was produced by 
inflating a balloon inside the descending colon through 
the anus; the inflation balloon had four pressure grades: 
20, 40, 60 and 80 mmHg. Each CRD lasted about 20 s and 
was repeated three times. AWR scores were produced 
blindly with no subjective judgment. The mean score for 
each rat was used for downstream analysis. The detailed 
grading rules on AWR scores are as follows: (0) no behav-
ioral response to CRD; (1) occasional head movement 
at the onset of the stimulus; (2) mild abdominal muscle 
contraction but no lifting; (3) strong abdominal muscle 
contraction and the abdomen but not pelvic structure 
being lifted off the platform; (4) body arching and lifting 
of pelvic structures off the platform.
Preparation of fecal and colon tissue samples
After calculating the AWR scores, rats were weighed and 
injected with 2% pentobarbital sodium (Sigma. USA. 
P3761). The colon samples (5 cm above the anus, 3 cm in 
length) were rapidly collected from the descending colon, 
5 g fecal matter was collected and stored at − 80  °C for 
16S rRNA sequencing. Then, colon samples were fixed in 
10% paraformaldehyde for hematoxylin–eosin staining 
for histopathological observation.
Fecal DNA extraction
Bacterial genomic DNA was extracted from all fecal sam-
ples using the QIAamp DNAMini Kit (QIAGEN, Ger-
many) according to the manufacturer’s instructions. First, 
100 mg fecal sample and 1.4 ml buffer ASL were added to 
a 2  ml tube. Next, 20 μl proteinase K was added to the 
tube and mixed well before incubation at 56 °C until the 
sample was fully dissolved. Next 200 μl buffer AL was 
added to the tube, mixed thoroughly, followed by incu-
bation at 70 °C for 10 min. Subsequently, 200 μl ethanol 
(96%) was added to the mixture, which was then loaded 
onto the QIAamp Mini spin column and centrifuged at 
8000  rpm for 1  min. The column material was washed 
with 500 μl buffer AW1 and centrifuged at 8000 rpm for 
1  min, then with 500 μl buffer AW2 and centrifuged at 
14,000 rpm for 3 min. Finally, the DNA was eluted in 100 
μl of AE elution buffer. DNA integrity and fragment size 
range was assessed by agarose gel electrophoresis, and 
DNA concentrations were measured using a NanoDrop 
ND-2000 spectrophotometer (Thermo Fisher Scientific, 
USA).
Illumina MiSeq sequencing
The V3–V4 region of the bacterial 16S rRNA gene was 
amplified by polymerase chain reaction (PCR) using 
universal bacterial primers 341F and 806R [25]. Pooled 
amplicons were sequenced on a 300 PE Illumina MiSeq. 
Demultiplexed reads were quality filtered based on 
sequence length and quality as previously described [26]. 
Operational taxonomic units (OTUs) were clustered at 
97% similarity, and chimeric sequences were removed 
using UCHIME [27]. Finally, taxonomic assignment of 
representative sequences was preformed using the Ribo-
somal Database Project (RDP) MultiClassifier tool [28].
Statistical analyses
AWR scores was analysed using SPSS21.0 software, and 
data were expressed as mean ± SD (Standard ± Devia-
tion) for normally distributed data and as M  (Q25–Q75) 
for non-normally distributed data. One-way analysis of 
variance (ANOVA) was performed for normally distrib-
uted data and a non-parametric test (Kruskal–Wallis H 
test.) was used for non-normally distributed data.
Bioinformatic analyses were performed using R 
3.2.3 (http://cran.r-proje ct.org). Differences in rela-
tive abundance between groups were assessed using the 
Kruskal–Wallis test. Alpha diversity was calculated using 
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Simpson’s diversity index. Beta diversity was determined 
by analysis of similarities (ANOSIM) using unweighted 
UniFrac as distance metric. In addition, OTUs that are 
differentially abundant were determined using Linear 
discriminant analysis effect size (LefSE). Results were 
deemed significant if P < 0.05.
Results
Abdominal withdrawal reflex (AWR) scores
As shown in Fig.  1, AWR scores were significantly 
increased in IBS model rats compared with normal rats 
at all four CRD pressures (P < 0.01). AWR scores were 
however significantly reduced in IBS model rats follow-
ing treatment with moxibustion at 20 (P < 0.05), 40, 60 
and 80 mmHg (P < 0.01). AWR scores of the EA, BTVC 
and PB groups also were significantly lower than in IBS 
model group (EA group: 20  mmHg P < 0.05, 40, 60 and 
80 mmHg, P < 0.01; BTVC group: 40 mmHg, P < 0.01; PB 
group: 20, 40 and 60 mmHg, P < 0.05, 80 mmHg, P < 0.01). 
These results suggest that moxibustion treatment could 
effectively decrease visceral hypersensitivity as EA, 
BTVC and PB.
Histological analysis
As shown in Fig. 2, there were no significant differences 
in histological features between groups. The colonic tis-
sue structure was normal in all groups, and the colonic 
mucosa epithelium was complete and had regularly 
arranged glands. There was no congestion, edema, ulcers, 
inflammatory cell infiltration or other pathological 
changes in any of the groups.
Gut microbial composition
A total of 3,759,276 high quality raw sequences were 
obtained using the MiSeq platform (Illumina, San Diego, 
CA, USA), and 2,802,729 filtered reads were retained after 
Fig. 1 Abdominal withdrawal reflex (AWR) scores under different distention pressure (a 20 mmHg, b 40 mmHg, c 60 mmHg, d 80 mmHg) in 
different groups. NC: normal group; MC: IBS model group; MOX: moxibustion group; EA: electroacupuncture group; BTVC: Bifid-triple Viable Capsule 
group; PB: Pinaverium Bromide group. Data are presented as Median,  Q25–Q75 (n = 7 per group). *P < 0.01, versus normal group; #P < 0.05, ▲P < 0.01, 
versus model group
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splicing and quality control with an average of 44,487 
reads per sample (ranging from 37,081 to 54,506 reads). 
Reads were then clustered into OTUs at 97% similarity 
resulting in 1361 OTUs, which were used for further taxa 
diversity analysis. In terms of microbial composition, the 
major phyla present across all groups were Bacteroidetes 
and Firmicutes, followed by Proteobacteria and Candida-
tus Saccharibacteria (Fig.  3a). At class level, Bacteroidia 
and Clostridia were the dominant taxa across all groups, 
followed by Bacilli and Alphaproteobacteria (Fig. 3b).
Comparison of gut microbial composition between normal 
and IBS model rats
At phylum level, both normal and IBS model rats had 
fecal samples dominated by the phyla Bacteroidetes and 
Firmicutes. However, the relative abundance of Bacteroi-
detes and Firmicutes varied significantly between groups. 
Compared with the normal group the model group had 
a higher relative abundance of Bacteroidetes and a lower 
relative abundance of Firmicutes (Fig. 4a). At genus level, 
the IBS model group had a higher relative abundance of 
the genera Prevotella, Bacteroides, Barnesiella, Para-
prevotella, Clostridium XI and Sphingomonas compared 
with normal samples, and a lower relative abundance 
of Lactobacillus, Clostridium XIVa and Oscillibacter 
(Fig. 4b).
Comparison of gut microbial composition between IBS 
model rats with and without moxibustion treatment
Treatment of IBS model rats with moxibustion led to a 
fecal microbial profile closer to that of normal rats, with 
decreased levels of Bacteroidetes and increased lev-
els of Firmicutes following treatment (Fig. 4a). At genus 
level Prevotella, Bacteroides and Clostridium XI were 
Fig. 2 Histopathological observation of rat colonic tissue in different group. There were no significant differences in histological features between 
groups. NC: normal group; MC: IBS model group; MOX: moxibustion group; EA: electroacupuncture group; BTVC: Bifid-triple Viable Capsule group; 
PB: Pinaverium Bromide group. (magnification: ×200)
Fig. 3 Comparison of overall community structure at phylum and class level by treatment group. a At phylum level, Bacteroidetes and Firmicutes 
were the dominant taxa across all groups, followed by Proteobacteria and Candidatus Saccharibacteria; b at class level, Bacteroidia and Clostridia were 
the dominant taxa across all groups, followed by Bacilli and Alphaproteobacteria. NC: normal group; MC: IBS model group; MOX: moxibustion group; 
EA: electroacupuncture group; BTVC: Bifid-triple Viable Capsule group; PB: Pinaverium Bromide group
(See figure on next page.)
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decreased in moxibustion-treated IBS rats while Lacto-
bacillus and Clostridium XIVa were increased in moxi-
bustion-treated IBS rats (Fig. 4b). The relative abundance 
values were presented in Additional file 2: Table S1.
Richness and diversity of gut bacterial communities
Alpha diversity, as measured by Simpson’s diversity index 
(Fig.  5), was significantly decreased in model compared 
with normal rats (P = 0.01). However, alpha diversity was 
increased following moxibustion treatment (P = 0.015). 
The EA, BTVC and PB groups also had higher alpha 
diversity than the model group, which suggests that all 
these treatments increase gut microbial diversity. With 
respect to beta diversity, principal coordinates analysis 
(PCoA) demonstrated significant differences between 
normal and model groups on the second axis (Fig. 6), sug-
gesting that disease may be the factor influencing micro-
bial community composition. However, the first and 
second principal coordinates only accounted for 15.04% 
and 8.93% of the total variations respectively, indicating 
that there are other factors affecting the IBS rats micro-
bial community or more-refined analysis needed. The 
microbial community composition from EA group was 
more similar to PB group, and moxibustion was more 
similar to BTVC on the first axis.
Fecal biomarkers of IBS and different treatments
Linear discriminant analysis effect size (LEfSe), a bio-
marker discovery tool for high dimensional data, was 
used to determine which OTUs were differentially 
abundant between normal and model samples and 
model and different treatments samples and hence 
potential biomarkers of IBS and different treatments 
(Fig. 7a, b). A total of 37 OTUs at different taxonomic 
levels were differentially abundant (P < 0.05) between 
Fig. 4 Microbiota comparison at phylum and genus level. a At phylum level, the relative abundance levels of Bacteroidetes was increased, whereas 
Firmicutes was decreased in the IBS model group compared with the normal group. These changes in microbiota profiles could be reversed by 
moxibustion, electroacupuncture, and Pinaverium Bromide treatment. b At genus level, IBS rats had decreased Lactobacillus and increased Prevotella 
and Bacteroides compared with the normal group. After treatment, Lactobacillus was increased and Prevotella was reduced in the moxibustion, 
electroacupuncture and Pinaverium Bromide groups. NC: normal group; MC: IBS model group; MOX: moxibustion group; EA: electroacupuncture 
group; BTVC: Bifid-triple Viable Capsule group; PB: Pinaverium Bromide group
Fig. 5 Alpha diversity of gut microbiota between groups. Alpha 
diversity was decreased in IBS model rats compared with normal 
rats, yet significantly increased in moxibustion- and Pinaverium 
Bromide-treated rats compared with IBS rats. NC: normal group; MC: 
IBS model group; MOX: moxibustion group; EA: electroacupuncture 
group; BTVC: Bifid-triple Viable Capsule group; PB: Pinaverium 
Bromide group
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normal and model samples. At phylum level, the rela-
tive abundance of Bacteroidetes and Firmicutes were 
increased and decreased in IBS model rats, respectively. 
At class level Bacterodia, Alphaproteobacteria, Betapro-
teobacteria and Erysipelotrichia were highly enriched 
in IBS model rats, while Epsilonproteobacteria and 
Clostridia were enriched in normal rats. At order level, 
Bacteroidales, Sphingomonadales, Burkholderiales and 
Erysipelotrichales were significantly enriched in the 
IBS model rats. At family level Porphyromonadaceae, 
Peptostreptococcaceae, Sphingomonadaceae, Sutterel-
laceae, Burkholderiales and Erysipelotrichaceae were 
enriched in IBS model rats, while Helicobacteraceae, 
Ruminococcaceae and Lachnospiraceae were enriched 
in normal rats. Similarly, the genera Advenella, Psychro-
bacter, Clostridium XI, Sphingomonas, Parasutterella 
and Aquabacterium were significantly more abundant 
in IBS model rats, whereas normal rats were enriched 
with Clostridium IV, Butyricicoccus, Saccharibacte-
ria, Helicobacter, Ruminococcus, Clostridium XIVa, 
and Faecalibacterium. These results are represented by 
heatmap analyses on a per-sample basis in Fig. 7c.
A total of 14 OTUs at different taxonomic levels were 
differentially abundant (P < 0.05) between MC and MOX 
group. Among them, compared with MC group, the rela-
tive abundance of Ruminococcaceae, Enterobacteriaceae, 
Clostridiaceae1, Enterobacteriales, Escherichia Shigella, 
Clostridiumsensustricto, Butyricicoccus and Enterorhab-
dus were significant abundant in MOX group which may 
be the potential biomarkers of the moxibustion to treat 
UC (Fig. 8a, b). A total of 17 OTUs at different taxonomic 
levels were differentially abundant (P < 0.05) between MC 
and EA group. Similarly, the relative abundance of Nega-
tivicutes, Selenomonadales, Gammaproteobacteria, Butt-
iauxella, Bacillaceae2, Butyricicoccus, Enterobacteriales, 
Enterobacteriaceae and Virgibacillus were significant 
Fig. 6 Beta diversity of gut microbiota between groups. It was showed that significant differences between normal and model groups on the 
second axis. NC: normal group; MC: IBS model group; MOX: moxibustion group; EA: electroacupuncture group; BTVC: Bifid-triple Viable Capsule 
group; PB: Pinaverium Bromide group
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abundant in EA group which may be the potential bio-
markers of the electroacupuncture to treat UC (Fig.  8c, 
d). Interestingly, Butyricicoccus, Enterobacteriales and 
Enterobacteriaceae were significant abundant both in 
MOX and EA group then MC group.
A total of 26 OTUs at different taxonomic levels were 
differentially abundant (P < 0.05) between MC and BTVC 
group. Among them, Clostridiales IncertaesedisXI and 
Parvimonas were significant abundant in BTVC group 
then MC group (Fig.  9a, b). A total of 81 OTUs at dif-
ferent taxonomic levels were differentially abundant 
(P < 0.05) between MC and PB group. Compared with 
MC group, there were 69 taxa significant abundant in 
PB group which may be the potential biomarkers of the 
Pinaverium Bromide to treat UC, such as Ruminococcus, 
Butyricicoccus, Fusobacteria, Deinococcales, Thermoto-
gae, Vibrionales, Epsilonproteobacteria and so on (Fig. 9c, 
d).
Discussion
IBS is characterized by several symptoms, including 
abdominal pain, that can seriously affect quality of life. 
Visceral hypersensitivity (enhanced intestinal percep-
tion) plays a significant role in such abdominal pain and 
discomfort [4]. In this study, we applied AWR scores 
to assess visceral hypersensitivity in rats. We found 
Fig. 7 Differentially abundant OTUs between normal and IBS model rats using LEfSe analysis. a Taxonomic cladogram of differences in the gut 
microbiota between normal and IBS model groups, blue shows tax enriched in normal group, red IBS model group and yellow non-significant. The 
diameter of each circle is proportional to the abundance of taxon. b The most abundant taxa in normal group with blue histogram and IBS model 
group with red histogram. c Heatmap of OTUs found to be significantly differentially abundant between normal and IBS model rats. NC: normal 
group; MC: IBS model group
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Fig. 8 Differentially abundant OTUs between IBS and moxibustion and electroacupuncture rats using LEfSe analysis. a Taxonomic cladogram of 
differences in the gut microbiota between IBS and moxibustion groups, blue shows tax enriched in IBS group, red moxibustion group and yellow 
non-significant. The diameter of each circle is proportional to the abundance of taxon. b The most abundant taxa in IBS group with blue histogram 
and moxibustion group with red histogram. c Taxonomic cladogram of differences in the gut microbiota between IBS and electroacupuncture 
groups, blue shows tax enriched in IBS group, red electroacupuncture group and yellow non-significant. The diameter of each circle is proportional 
to the abundance of taxon. d The most abundant taxa in IBS group with blue histogram and electroacupuncture group with red histogram. MC: IBS 
model group; MOX: moxibustion group; EA: electroacupuncture group
Fig. 9 Differentially abundant OTUs between IBS and Bifid-triple Viable Capsule and Pinaverium Bromide rats using LEfSe analysis. a Taxonomic 
cladogram of differences in the gut microbiota between IBS and Bifid-triple Viable Capsule groups, blue shows tax enriched in IBS group, red 
Bifid-triple Viable Capsule group and yellow non-significant. The diameter of each circle is proportional to the abundance of taxon. b The most 
abundant taxa in IBS group with blue histogram and Bifid-triple Viable Capsule group with red histogram. c Taxonomic cladogram of differences in 
the gut microbiota between IBS and Pinaverium Bromide groups, blue shows tax enriched in IBS group, red Pinaverium Bromide group and yellow 
non-significant. The diameter of each circle is proportional to the abundance of taxon. d The most abundant taxa in IBS group with blue histogram 
and Pinaverium Bromide group with red histogram. MC: IBS model group; BTVC: Bifid-triple Viable Capsule group; PB: Pinaverium Bromide group
(See figure on next page.)
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that AWR scores of IBS model rats were significantly 
increased compared with normal rats. Certain studies 
have shown that patients with IBS have a higher pain 
sensitivity and lower pain threshold than normal sub-
jects [29]—our results support these findings. More 
importantly, AWR scores of IBS rats were significantly 
decreased in moxibustion, EA, BTVC and PB groups, 
which demonstrates that moxibustion and EA can effec-
tively alleviated abdominal pain by increasing pain 
threshold and decreasing visceral hypersensitivity in IBS 
rats as Pinaverium Bromide and Bifid-triple Viable Cap-
sule. Several studies have reported that electroacupunc-
ture [30], probiotic [31] and Pinaverium Bromide [32] 
have therapeutic effect for IBS. Our findings indicate that 
moxibustion may potentially be used as an alternative 
treatment to Bifid-triple Viable Capsule and Pinaverium 
Bromide.
The intestinal microbiota profoundly affects human 
health through various means. Commensal bacteria pro-
mote proper functioning of the physical and biochemi-
cal barrier against pathogens as well as immune system 
development [33]. Intestinal bacteria and their meta-
bolic products interact with the host gut mucosal surface 
thereby shaping the host immune system. Under healthy 
conditions the host’s response to these bacterial signals 
will result in immune tolerance. Normal intestinal micro-
biota play a critical role in promoting immune system 
development, sustaining normal immune function, and 
preventing infection by pathogens [34]. However, when 
dysbacteriosis occurs the balance between tolerance 
towards commensals and immune activation in response 
to pathogens may be lost, which may lead to a range of 
diseases.
Tianshu and Shangjuxu acupoints are ancient and clas-
sical acupoint combination for intestinal diseases such 
as diarrhea and abdominal pain [35]. Numerous studies 
suggest that dysbacteriosis is closely related to the patho-
physiology of IBS [36]. Moxibustion has proven benefits 
in treating IBS [37]. However, ours is the first study to 
examine the effect of moxibustion on the gut microbiota 
in IBS. We analyzed changes in gut microbiota between 
IBS and normal rats and the effect of moxibustion ther-
apy on the gut microbiota.
We found that the intestinal microbial composition of 
IBS rats differed from that of normal rats. IBS rats had 
significantly decreased alpha diversity and increased 
relative abundance of Bacteroidetes, which is consist-
ent with previous reports [38]. Several studies have 
now reported that IBS patients and IBS model rats have 
significantly reduced levels of Lactobacillus [39, 40]. 
Lactobacillus is a major component of the commensal 
bacterial flora of the human intestinal tract, and is fre-
quently used as a probiotic as it induces the production 
of large quantities of anti-inflammatory interleukins 
that improve intestinal barrier function, thus prevent-
ing the development of colitis [41]. Several studies 
have shown that Lactobacillus GG—a specific probi-
otic strain of Lactobacillus (ATCC 53103)—effectively 
treats IBS in humans and rats [42–44]. Indeed, in our 
study, Lactobacillus was decreased in IBS rats, as were 
Clostridium XIVa and Oscillibacter. Further, Prevotella, 
Bacteroides and Clostridium XI were increased in IBS 
model rats. Interestingly however, these IBS-related 
changes in gut microbiota could be normalized by mox-
ibustion treatment, after which the relative abundance 
of Lactobacillus and Clostridium XIVa increased, while 
Prevotella, Bacteroides and Clostridium XI decreased. 
In addition, moxibustion treatment led to increased gut 
microbiota diversity, as did the other treatments con-
sidered in this study (EA, BTVC, and PB) to varying 
degrees.
We conducted LEfSe to discover distinctive features at 
all levels which may be the potential biomarkers of the 
IBS. Twenty-one features were discovered by LEfSe, and 
the relative abundance of Bacteroidia, Bacteroidales and 
Bacteroidetes, which exhibited the top three highest LDA 
score suggesting that these features may be closely related 
to IBS. We have also identified some potential markers 
that may play a therapeutic role in different treatments. It 
was an interesting finding that Butyricicoccus, Enterobac-
teriales and Enterobacteriaceae were significant abundant 
both in MOX and EA group compared to MC group. This 
suggests that moxibustion and electroacupuncture may 
have some similar therapeutic targets. Although we have 
found some potential biomarkers, how to regulate these 
markers by moxibustion and electroacupuncture still 
requires further research.
Conclusions
Our findings suggest that moxibustion treats IBS by 
modulating the gut microbiota. We demonstrate that 
moxibustion could potentially be used to regulate gut 
microbiota imbalances and therefore to treat patients 
with IBS.
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